Subudhi et al. found that in prostate cancer patients treated with ICIs, expansion of ≥ 55 CD8 T cell clones preceded the development of grade 2–3 irAEs.122 Additionally, detection of autoantibody in the serum is another potential predictor for the occurrence of irAEs. The gene discussed is CD8A; the disease is prostate carcinoma.